Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H25N3S.2C4H4O4 |
| Molecular Weight | 571.642 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CN1CCN(CCCN2C3=C(SC4=C2C=CC=C4)C=CC=C3)CC1
InChI
InChIKey=PQDKNYWKLCFCJU-SPIKMXEPSA-N
InChI=1S/C20H25N3S.2C4H4O4/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23;2*5-3(6)1-2-4(7)8/h2-5,7-10H,6,11-16H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
| Molecular Formula | C20H25N3S |
| Molecular Weight | 339.498 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/12523495 and http://www.genome.jp/dbget-bin/www_bget?D01412
Curator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/12523495 and http://www.genome.jp/dbget-bin/www_bget?D01412
Perazine (Taxilan) is a moderate-potency typical antipsychotic of the phenothiazine class. Perazine is an older antipsychotic drug first introduced in the 1950s. It is suggested to have a low level of side effects (especially for movement disorders). Its use is regional and restricted to countries like Germany, Poland, the Netherlands and the former Yugoslavia. Perazine has being shown to be a potent inhibitor of human CYP1A2. It acts as a dopamine antagonist.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3356 |
|||
Target ID: CHEMBL217 |
|||
Target ID: Cytochrome P450 2B, Rattus norvegicus |
45.0 µM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Taxilan Approved UseTaxilan is used in the treatment of schizophrenia |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Neurologic complications in patients treated with lithium. | 1988 Sep |
|
| [Electroconvulsive therapy in treatment of acute life threatening catatonia in toxic epidermal necrolysis (Lyell syndrome)]. | 1992 May |
|
| An acute psychotic disorder caused by pefloxacin: a case report. | 1996 Feb |
|
| [Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia]. | 2001 Jan-Feb |
|
| Switching to amisulpride due to hepatic complications. | 2002 May |
|
| Schizophrenia. | 2003 Dec |
|
| Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions. | 2003 Feb |
|
| Blood dyscrasias induced by psychotropic drugs. | 2004 Mar |
|
| The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes. | 2004 May |
|
| Acute psychosis with a mediastinal carcinoma metastasis. | 2005 Jan |
|
| Interactions between neuroleptics and CYP2C6 in rat liver--in vitro and ex vivo study. | 2005 Nov-Dec |
|
| Direct effects of neuroleptics on the activity of CYP2A in the liver of rats. | 2005 Nov-Dec |
|
| Effect of chronic treatment with perazine on lipopolysaccharide-induced interleukin-1 beta levels in the rat brain. | 2006 Apr |
|
| Perazine for schizophrenia. | 2006 Apr 19 |
|
| Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. | 2006 Mar |
|
| Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. | 2006 Oct 20 |
|
| Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. | 2008 Jun |
|
| [Application of liquid chromatography coupled with mass spectrometry (LC/MS) to determine antidepressants in blood samples]. | 2008 Oct-Dec |
|
| [Perazine in the treatment of psychotic disorders--research review]. | 2010 May-Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: In acutely ill and severely disturbed patients 50 mg perazine at time-intervals of 30 minutes can be administered intramuscularly
The customary dose range recommended for this antipsychotic under in-patient conditions is 75-600 mg/day (maximum 1000 mg/day).
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:59:01 GMT 2023
by
admin
on
Fri Dec 15 16:59:01 GMT 2023
|
| Record UNII |
3VG1507988
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000079420
Created by
admin on Fri Dec 15 16:59:01 GMT 2023 , Edited by admin on Fri Dec 15 16:59:01 GMT 2023
|
PRIMARY | |||
|
5282417
Created by
admin on Fri Dec 15 16:59:01 GMT 2023 , Edited by admin on Fri Dec 15 16:59:01 GMT 2023
|
PRIMARY | |||
|
14516-56-4
Created by
admin on Fri Dec 15 16:59:01 GMT 2023 , Edited by admin on Fri Dec 15 16:59:01 GMT 2023
|
PRIMARY | |||
|
SUB14812MIG
Created by
admin on Fri Dec 15 16:59:01 GMT 2023 , Edited by admin on Fri Dec 15 16:59:01 GMT 2023
|
PRIMARY | |||
|
3VG1507988
Created by
admin on Fri Dec 15 16:59:01 GMT 2023 , Edited by admin on Fri Dec 15 16:59:01 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |